LOX and prostate carcinoma: To date, a decrease in LOX mRNA and/or protein has been observed in basal and squamous cell, bronchogenic, colon, esophageal, gastric, head and neck squamous cell, pancreatic, and prostatic carcinomas, as well as osteosarcoma [31].